Full text is available at the source.
Abstract
GLP-1 receptor agonist therapy may reduce 1-year atrial fibrillation incidence in non-diabetic adults with obesity and chronic kidney disease.
- Obesity and chronic kidney disease are known risk factors for developing atrial fibrillation.
- The effect of GLP-1 receptor agonists on atrial fibrillation in this specific patient population is currently unknown.
- This assessment focuses on the potential preventive role of GLP-1 receptor agonists for incident atrial fibrillation.
Simplified